Clinical Trials Logo

Pneumonia clinical trials

View clinical trials related to Pneumonia.

Filter by:

NCT ID: NCT06146400 Not yet recruiting - Clinical trials for Pediatric Infectious Disease

Role of CBC Parameters in Early Diagnosis of Pediatric Pneumonia

Start date: December 2023
Phase:
Study type: Observational

Detection of the role of Complete Blood Count (CBC) parameters in early diagnosis of pediatric pneumonia -Testing the ability of Complete Blood Count (CBC) parameters (N/L ratio, PLT /MPV ratio, MPV and other parameters) to differentiate between viral and bacterial pneumonia.

NCT ID: NCT06124092 Not yet recruiting - Sepsis Clinical Trials

Outcomes of Children After Hospitalization in Intensive Care Unit

APCI
Start date: March 2024
Phase:
Study type: Observational

More than 10,000 children are hospitalized in an PICU every year in Canada. While most of them will survive their PICU hospitalization and their critical illness, some children will not recover to their pre-illness level. Some may develop behavioral, physical, emotional or developmental problems and difficulties at school. All these problems are elements that are part of the Pediatric Post-Intensive Care Syndrome (PICS-p). It is important to understand the elements (risk factors) that play a role in the development of PICS-p. In Canada, there is no systematic follow-up for children after they leave the PICU. Understanding what can cause PICS-p (risk factors) and how much PICS-p has an impact on children and their family is very important to the family well-being.

NCT ID: NCT06118242 Not yet recruiting - Clinical trials for Ventilator-Associated Pneumonia

The Effect of Solutions Used in Oral Care on Preventing Ventilator-Associated Pneumonia.

Start date: November 15, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about effects of chlorhexidine gluconate, sodium bicarbonate, ozonated water and hypochlorous acid solutions used in oral care of patients on mechanical ventilation support on preventing ventilator associated pneumonia. The main question[s] it aims to answer are: Is there any difference between 1% chlorhexidine gluconate, sodium bicarbonate, ozonated water and hypochlorous acid solutions versus 0.12% chlorhexidine gluconate solution used in oral care in preventing the development of VAP? Is there any difference between 1% chlorhexidine gluconate, sodium bicarbonate, ozonated water and hypochlorous acid solutions versus 0.12% chlorhexidine gluconate solution used in oral care in preventing the development of VAP? Researchers will compare 1% chlorhexidine gluconate, sodium bicarbonate, ozonated water and hypochlorous acid solutions to see if VAP

NCT ID: NCT06117826 Not yet recruiting - Acute Kidney Injury Clinical Trials

Incidince of Acute Kidney Injury in Children With Community Acquired Pneumonia at Assiut University Children Hospital

Start date: June 30, 2024
Phase:
Study type: Observational

Descriptive prospective observational study of Incidince of acute kidney injury in children with community acquired pneumonia at assiut university children hospital

NCT ID: NCT06113939 Not yet recruiting - Cardiac Arrest Clinical Trials

Prevention of Infection of the Respiratory Tract Through Application of Non-Invasive Methods of Secretion Suctioning

PIRAMIDES
Start date: July 2024
Phase: N/A
Study type: Interventional

Severe trauma, head trauma, stroke and resuscitated cardiac arrest patients requiring endotracheal intubation and mechanical ventilation are at high risk of early-onset ventilator-associated pneumonia (EO-VAP). A short course of systemic antibiotic is recommended for prophylaxis. This study intends to assess the safety and efficacy of 2 alternative mechanical non-invasive airway clearance techniques in the prevention of EO-VAP in an open label randomized pilot trial of 20 subjects per study group i.e., 60 cases. The interventions will be in place for 7 days and the observational periods will be 14 days.

NCT ID: NCT06105814 Not yet recruiting - Pneumonia Clinical Trials

Improved Diagnostics, Treatment and Follow-up of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

COPEXNOR
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

Chronic obstructive pulmonary disease (COPD) is a chronic and often progressive pulmonary disease, where inflammation and recurrent infections are key pathophysiological contibutors in disease progression. Acute exacerbations of COPD (AECOPD) are often treated with antibiotics, even though only about 50% are caused by bacteria, and the evidence for benefit of empiric antibiotic treatment in AECOPD is conflicting. Microbiological sampling is often insufficient in the setting of AECOPD, and there is a lack of biomarkers distinguishing AECOPD caused by bacteria from those not caused by bacteria, leaving the clinician with few tools to guide the use of antibiotics. Overuse of antibiotics is the main driver of antimicrobial resistance (AMR), a major global public health threat, and obtaining the correct microbiological diagnose is important in guiding treatment of AECOPD. COPEXNOR seeks to examine which samples give the highest microbiological yield in AECOPD, comparing induced sputum to nasopharyngeal swabs. We will also compare conventional microbiological diagnostics to modern rapid molecular microbiological tests, to evaluate if faster microbiological diagnosis improves antibiotic stewardship. The study aims to define the microbiological etiology causing AECOPD in the Norwegian COPD-population, and examine the lung microbiome over time. COPEXNOR will explore biomarkers in sputum and blood that can be useful for differentiating patients who will benefit from antibiotic treatment from patients who will not.

NCT ID: NCT06103981 Not yet recruiting - Pneumonia Clinical Trials

Acute Liver Injury in Patients With Pneumonia

Start date: December 1, 2023
Phase:
Study type: Observational

Acute liver injury (ALI) is defined as an acute derangement in liver function tests associated with liver-related coagulopathy, in the absence of underlying chronic liver disease. A subset progress to acute liver failure ,Acute liver failure represent a more severe liver injury results in hepatic encephalopathy

NCT ID: NCT06097117 Not yet recruiting - Clinical trials for Community-acquired Pneumonia

Role of Multiplex PCR in CAP

Start date: November 1, 2023
Phase:
Study type: Observational

1. role of multiplex PCR in early identifying bacteria in patients with lower respiratory tract infection. 2. effect of early starting targeted antibiotics on outcome

NCT ID: NCT06090032 Not yet recruiting - Clinical trials for Respiratory Intensive Care Unit Patients With Ventilator Associated Pneumonia

Compined SONOPULMONARY Infection Score and APACHE Score in RICU Patients With VAP

Start date: November 1, 2023
Phase:
Study type: Observational

Aim of the study : 1. Efficacy of Sono pulmonary infection score in combination with APACHE score in early diagnosis of VAP 2. Assessment of prediction role of combined SIPS SCORE and APACHE SCORE of outcome of VAP patient in RICU 3. Assessments of role of ultrasonography in early diagnosis and follow up of VAP

NCT ID: NCT06087536 Not yet recruiting - Clinical trials for Ventilator-associated Bacterial Pneumonia

A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex

Start date: January 2024
Phase: Phase 2
Study type: Interventional

This is a phase 2a, multinational, multicenter, double-blind, randomized, placebo-controlled, dose-ranging safety, tolerability and PK study in patients with HABP (Hospital Acquired Bacterial Pneumonia) or VABP (Ventilator Associated Bacterial Pneumonia) caused by ABC to identify safe and well-tolerated doses and to assess the PK profile of OMN6 in patients.